lorazepam has been researched along with Blood Poisoning in 3 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Of the 103 patients randomized, 63 (31 dexmedetomidine; 32 lorazepam) were admitted with sepsis and 40 (21 dexmedetomidine; 19 lorazepam) without sepsis." | 9.14 | Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. ( Ely, EW; Girard, TD; Herr, DL; Maze, M; McGrane, S; Pandharipande, PP; Sanders, RD; Shintani, AK; Thompson, JL, 2010) |
| "Of the 103 patients randomized, 63 (31 dexmedetomidine; 32 lorazepam) were admitted with sepsis and 40 (21 dexmedetomidine; 19 lorazepam) without sepsis." | 5.14 | Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. ( Ely, EW; Girard, TD; Herr, DL; Maze, M; McGrane, S; Pandharipande, PP; Sanders, RD; Shintani, AK; Thompson, JL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| OʼRear, JM | 1 |
| Prahlow, JA | 1 |
| Pandharipande, PP | 1 |
| Sanders, RD | 1 |
| Girard, TD | 1 |
| McGrane, S | 1 |
| Thompson, JL | 1 |
| Shintani, AK | 1 |
| Herr, DL | 1 |
| Maze, M | 1 |
| Ely, EW | 1 |
| Kress, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status[NCT00095251] | Phase 2 | 100 participants (Anticipated) | Interventional | 2004-08-31 | Completed | ||
| PRO-DEFENSE: Propofol Versus Dexmedetomidine for Sedation in Mechanically Ventilated Patients With Sepsis[NCT02203019] | Phase 4 | 36 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Multicentric, Single Blind, Randomized Controlled Trial on Enteral Sedation Versus Intravenous Sedation in Critically Ill High-risk ICU Patients[NCT01360346] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| Pain, Agitation and Delirium Protocol in Ventilated Patients in the Duke CICU[NCT02903407] | Phase 4 | 7 participants (Actual) | Interventional | 2017-09-01 | Terminated (stopped due to All enrolled participants completed the study protocol but the study was terminated prior to the goal number of participants due to low recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of days patient requires mechanical ventilation (NCT02203019)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Propofol | 5 |
| Dexmedetomidine | 3 |
Number of days patient stays in the MICU (NCT02203019)
Timeframe: Up to 28 Days
| Intervention | days (Median) |
|---|---|
| Propofol | 6 |
| Dexmedetomidine | 5 |
Number of days the patient requires intravenous vasopressors (NCT02203019)
Timeframe: Up to 28 Days
| Intervention | days (Median) |
|---|---|
| Propofol | 0 |
| Dexmedetomidine | 2 |
Number of patients who die within 28 days after randomization (NCT02203019)
Timeframe: Up to 28 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Propofol | 8 |
| Dexmedetomidine | 9 |
Index hospitalization length of stay in days (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Days (Median) |
|---|---|
| Midazolam | 19.5 |
| Propofol or Dexmedetomidine | 30.0 |
All-cause mortality during the hospitalization (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | participants (Number) |
|---|---|
| Midazolam | 1 |
| Propofol or Dexmedetomidine | 1 |
Number of days of admission to the CICU during the index hospitalization (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Days (Median) |
|---|---|
| Midazolam | 4.1 |
| Propofol or Dexmedetomidine | 10.0 |
The number of days alive and free from delirium or coma during admission will be evaluated among patients with CAM-ICU documented (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Days (Median) |
|---|---|
| Midazolam | 14.0 |
The time (in days) from when the clinical care team documents a decision to pursue extubation until the time the patient was extubated (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Days (Median) |
|---|---|
| Midazolam | 0 |
| Propofol or Dexmedetomidine | 0 |
Following ICU discharge, patient charts will be reviewed to evaluate whether they required reintubation. If so, will determine whether necessity of reintubation was related to delirium. (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Participants (Count of Participants) |
|---|---|
| Midazolam | 0 |
| Propofol or Dexmedetomidine | 1 |
Patients will be monitored for bradycardia which may be associated with sedation drug. Average heart rate before, during and after use of drug will be recorded for each patient. (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Participants (Count of Participants) |
|---|---|
| Midazolam | 0 |
| Propofol or Dexmedetomidine | 0 |
Will use the Confusion Assessment Method for the ICU (CAM-ICU) to assess presence of delirium as per standard of care by nurses in the CICU. Patients with CAM-ICU data recorded will be included. (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Participants (Count of Participants) |
|---|---|
| Midazolam | 1 |
Patients will be monitored for increased pressor requirement during the CICU stay (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Participants (Count of Participants) |
|---|---|
| Midazolam | 2 |
| Propofol or Dexmedetomidine | 2 |
Days requiring mechanical ventilation during the initial episode of intubation during the hospitalization (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Days (Median) |
|---|---|
| Midazolam | 2.5 |
| Propofol or Dexmedetomidine | 6.8 |
Will use the CPOT (Critical-Care Pain Observation Tool) score to assess pain level as per standard of care by nurses in the CICU. The CPOT has a range of 0 to 8. A CPOT score of ≤ 2 = minimal to no pain present and >2 = unacceptable level of pain. Data that is recorded will be evaluated following discharge. (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | score on a scale (Median) |
|---|---|
| Midazolam | 0.0 |
| Propofol or Dexmedetomidine | 0.0 |
Will use RASS (Richmond Agitation and Sedation Scale) to assess level of sedation as per standard of care by nurses in the CICU. Data that is recorded will be evaluated following discharge. The RASS ranges from -5 (unrousable) to +4 (combative) and 0 (zero) = alert and calm and goal sedation is considered a RASS level of 0 to -2. (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | percentage of time (Median) |
|---|---|
| Midazolam | 63.3 |
| Propofol or Dexmedetomidine | 63.2 |
The duration, in days, from withdrawal of sedation for mechanical ventilation until the time of discharge from the ICU (NCT02903407)
Timeframe: One month or hospital discharge, whichever time point comes first
| Intervention | Days (Median) |
|---|---|
| Midazolam | 1.6 |
| Propofol or Dexmedetomidine | 5.6 |
1 trial available for lorazepam and Blood Poisoning
| Article | Year |
|---|---|
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.
Topics: Adult; Aged; Coma; Delirium; Dexmedetomidine; Double-Blind Method; Female; Humans; Hypnotics and Sed | 2010 |
2 other studies available for lorazepam and Blood Poisoning
| Article | Year |
|---|---|
Early percutaneous endoscopic gastrostomy tube dislodgment.
Topics: Accidents, Traffic; Anti-Anxiety Agents; Craniotomy; Enteral Nutrition; Equipment Failure Analysis; | 2015 |
The complex interplay between delirium, sepsis and sedation.
Topics: Brain; Critical Illness; Delirium; Dexmedetomidine; Humans; Hypnotics and Sedatives; Intensive Care | 2010 |